Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
You may also be interested in...
Marooned! VCs Stuck in the Public Markets
One group badly hurt by the miserable public market: VCs who remain stuck in companies they took public too early. We review the most threatened companies among those companies that went public since 2003, showing why financing risk is now as important to VCs as regulatory and clinical risk. Meanwhile, current investors are recalibrating, way down, the price at which they can raise new money.
Archemix Reduces Aperture to Pursue Orphan Diseases
Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?